PL3475425T3 - Leczenie niealkoholowego stłuszczeniowego zapalenia wątroby (nash) - Google Patents

Leczenie niealkoholowego stłuszczeniowego zapalenia wątroby (nash)

Info

Publication number
PL3475425T3
PL3475425T3 PL17732939T PL17732939T PL3475425T3 PL 3475425 T3 PL3475425 T3 PL 3475425T3 PL 17732939 T PL17732939 T PL 17732939T PL 17732939 T PL17732939 T PL 17732939T PL 3475425 T3 PL3475425 T3 PL 3475425T3
Authority
PL
Poland
Prior art keywords
nash
treatments
alcoholic steatohepatitis
steatohepatitis
alcoholic
Prior art date
Application number
PL17732939T
Other languages
English (en)
Inventor
Mathias HEIKENWÄLDER
Lars Zender
Achim Weber
Original Assignee
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts filed Critical Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts
Publication of PL3475425T3 publication Critical patent/PL3475425T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Detergent Compositions (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL17732939T 2016-06-28 2017-06-28 Leczenie niealkoholowego stłuszczeniowego zapalenia wątroby (nash) PL3475425T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16176755.3A EP3263705A1 (en) 2016-06-28 2016-06-28 Treatments of non-alcoholic steatohepatitis (nash)
PCT/EP2017/066025 WO2018002155A1 (en) 2016-06-28 2017-06-28 Treatments of non-alcoholic steatohepatitis (nash)
EP17732939.8A EP3475425B1 (en) 2016-06-28 2017-06-28 Treatments of non-alcoholic steatohepatitis (nash)

Publications (1)

Publication Number Publication Date
PL3475425T3 true PL3475425T3 (pl) 2022-01-17

Family

ID=56296569

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17732939T PL3475425T3 (pl) 2016-06-28 2017-06-28 Leczenie niealkoholowego stłuszczeniowego zapalenia wątroby (nash)

Country Status (14)

Country Link
US (3) US11052102B2 (pl)
EP (3) EP3263705A1 (pl)
JP (3) JP7165058B2 (pl)
CY (1) CY1124611T1 (pl)
ES (1) ES2894914T3 (pl)
HR (1) HRP20211727T1 (pl)
HU (1) HUE056986T2 (pl)
LT (1) LT3475425T (pl)
PL (1) PL3475425T3 (pl)
PT (1) PT3475425T (pl)
RS (1) RS62622B1 (pl)
SI (1) SI3475425T1 (pl)
SM (1) SMT202100654T1 (pl)
WO (1) WO2018002155A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3785731A1 (en) * 2019-08-28 2021-03-03 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Treating non-alcoholic steatohepatitis (nash) and hepatocellular carcinoma (hcc) with compounds binding the ectodomain of platelet glycoprotein ib (gpib) alpha
CN110859838A (zh) * 2019-12-19 2020-03-06 南京市第一医院 氯吡格雷在制备预防或治疗非酒精性脂肪肝的药物中的应用
WO2026057679A1 (en) * 2024-09-11 2026-03-19 Institut National de la Santé et de la Recherche Médicale Inhibitor of rab30 for use in a method of treatment of metabolic dysfunction-associated steatotic liver disease (masld)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006045550A1 (de) * 2006-09-25 2008-04-03 Dade Behring Marburg Gmbh Verfahren zur Herstellung von agglutionationsfähigen Thrombozytenfragmenten und deren Verwendung
AR067446A1 (es) * 2007-07-11 2009-10-14 Otsuka Pharma Co Ltd Un medicamento para tratar higado graso que comprende cilostazol
US20110082119A1 (en) * 2008-06-13 2011-04-07 Takashi Yano Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis

Also Published As

Publication number Publication date
US20210213042A1 (en) 2021-07-15
US20240024349A1 (en) 2024-01-25
JP7441921B2 (ja) 2024-03-01
ES2894914T3 (es) 2022-02-16
JP7672526B2 (ja) 2025-05-07
US20190262379A1 (en) 2019-08-29
JP2024065114A (ja) 2024-05-14
CY1124611T1 (el) 2022-07-22
LT3475425T (lt) 2021-11-10
JP7165058B2 (ja) 2022-11-02
HUE056986T2 (hu) 2022-04-28
EP3263705A1 (en) 2018-01-03
US11052102B2 (en) 2021-07-06
JP2019524659A (ja) 2019-09-05
PT3475425T (pt) 2021-10-26
EP3475425B1 (en) 2021-08-25
EP3475425A1 (en) 2019-05-01
SI3475425T1 (sl) 2021-12-31
EP3913057A1 (en) 2021-11-24
US11806361B2 (en) 2023-11-07
JP2023002696A (ja) 2023-01-10
SMT202100654T1 (it) 2022-01-10
RS62622B1 (sr) 2021-12-31
HRP20211727T1 (hr) 2022-02-18
WO2018002155A1 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
IL248193B (en) Compositions for use in treating nafld and nash
ZA201807083B (en) Non-invasive diagnostic of non-alcoholic steatohepatitis
EP3445385A4 (en) THERAPEUTIC GOALS INVOLVED IN THE PROGRESSION OF NON-ALCOHOLIC STEATOHEPATITIS (NASH)
SG11201507288UA (en) Compositions and methods for treating non-alcoholic steatohepatitis
ZA201706257B (en) Treatment of wood
SG11201609652RA (en) Treatment of polybacterials infections
LT3458052T (lt) Vėžio kombinuotas gydymas
ZA201902090B (en) Combination treatments comprising administration of imidazopyrazinones
IL267647A (en) Combined treatment of non-alcoholic steatohepatitis (nash) and liver fibrosis
IL263835A (en) Exosome-guided treatment of cancer
HUS2400045I1 (hu) Delgocitinib alkalmazása krónikus kézekcéma kezelésére
IL271236A (en) Licofligozin for the treatment of non-alcoholic steatohepatitis
EP3624800A4 (en) TREATMENT OF HEPATOCELLULAR CARCINOMA
SMT202100654T1 (it) Trattamenti della steatoepatite non alcolica (nash)
GB2548491B (en) Treatment of fluids
SMT202100037T1 (it) Trattamento dell'emicrania con acetil-leucina
EP3139911A4 (en) Method of treating advanced non-alcoholic steatohepatitis
IL278077A (en) A treatment method for non-alcoholic steatohepatitis, NASH
IL274770A (en) Anti-huTNFR1 therapy in non-alcoholic steatohepatitis
HK40017104A (en) Licofligozin for the treatment of non-alcoholic steatohepatitis
HK40035976A (en) Anti-hutnfr1 therapy of nonalcoholic steatohepatitis
HK40001613A (en) Use of sgc stimulators for the treatment of nonalcoholic steatohepatitis (nash)
GB201622214D0 (en) treatment of cancer
GB201523018D0 (en) The traditional chinese medicine combination for the treatment of prostate
GB201604621D0 (en) Treatment of cancer